THE US Food and Drug Administration has approved Galafold (migalastat), which is the first medication for adults with hereditary disorder Fabry Disease.
Patients with the condition develop slowly progressive kidney disease, cardiac hypertrophy, arrhythmias, stroke and early death.
Galafold treats Fabry disease by targeting a type of fat that builds up in the organs.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Aug 18
